Literature DB >> 8800923

Distribution of CFTR mutations in cystic fibrosis patients of Tunisian origin: identification of two novel mutations.

T Messaoud1, C Verlingue, E Denamur, O Pascaud, I Quéré, S Fattoum, J Elion, C Férec.   

Abstract

Cystic fibrosis (CF), the most common lethal genetic disease in the Caucasian population, is caused by mutations in the CF transmembrane conductance regulator gene (CFTR). More than 500 molecular defects have been reported to date. The distribution of these mutations is both heterogeneous and population related. In Mediterranean populations, 20-30% of CF alleles remain unidentified. We have studied a sample of 39 CF patients of Tunisian origin and have used a GC clamp DGGE assay to scan the CFTR gene. Two novel mutations have been found, but we have been unsuccessful in finding any mutation in 40% of these alleles. These results suggest that, in this Mediterranean population, additional mutations may lie elsewhere in the promoter region or in introns not yet analyzed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8800923     DOI: 10.1159/000472165

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  9 in total

1.  A haplotype framework for cystic fibrosis mutations in Iran.

Authors:  Elahe Elahi; Ahmad Khodadad; Ilya Kupershmidt; Fereshteh Ghasemi; Babak Alinasab; Ramin Naghizadeh; Robert G Eason; Mahshid Amini; Mehran Esmaili; Mohammad R Esmaeili Dooki; Mohammad H Sanati; Ronald W Davis; Mostafa Ronaghi; Yvonne R Thorstenson
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

2.  Multiplex ligation-dependent probe amplification identification of whole exon and single nucleotide deletions in the CFTR gene of Hispanic individuals with cystic fibrosis.

Authors:  Iris Schrijver; Krista Rappahahn; Lynn Pique; Martin Kharrazi; Lee-Jun Wong
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

3.  New frameshift CF mutation 3729delAinsTCT in a Tunisian cystic fibrosis patient.

Authors:  Sondess Hadj Fredj; Monia Boudaya; Sabrine Oueslati; Safa Sahnoun; Chaima Sahli; Hajer Siala; Khedija Boussetta; Amina Bibi; Taieb Messaoud
Journal:  J Genet       Date:  2013-04       Impact factor: 1.166

4.  Prediction of cellular immune responses against CFTR in patients with cystic fibrosis after gene therapy.

Authors:  Joanita Figueredo; Maria P Limberis; James M Wilson
Journal:  Am J Respir Cell Mol Biol       Date:  2007-01-11       Impact factor: 6.914

5.  Absence of mutations in the interspecies conserved regions of the CFTR promoter region in cystic fibrosis (CF) and CF related patients.

Authors:  C Verlingue; S Vuillaumier; B Mercier; M Le Gac; J Elion; C Férec; E Denamur
Journal:  J Med Genet       Date:  1998-02       Impact factor: 6.318

6.  Novel and characteristic CFTR mutations in Saudi Arab children with severe cystic fibrosis.

Authors:  E A el-Harith; T Dörk; M Stuhrmann; H Abu-Srair; A al-Shahri; K M Keller; M J Lentze; J Schmidtke
Journal:  J Med Genet       Date:  1997-12       Impact factor: 6.318

Review 7.  Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date.

Authors:  Frédéric Becq
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

8.  Mutation Analysis of Exons 10 and 17a of CFTR Gene in Patients with Cystic Fibrosis in Kermanshah Province, Western Iran.

Authors:  Abbas Sahami; Reza Alibakhshi; Keyghobad Ghadiri; Hamid Sadeghi
Journal:  J Reprod Infertil       Date:  2014-01

9.  The Incidence of Cystic Fibrosis in the Central Region of Anatolia in Turkey Between 2015 and 2016

Authors:  Melih Hangül; Sevgi Pekcan; Mehmet Köse; Deniz Acıcan; Tuba Esra Şahlar; Murat Erdoğan; Mustafa Kendirci; Deniz Güney; Hasan Öznavruz; Osman Demir; Ömür Ercan; Fatma Göçlü
Journal:  Balkan Med J       Date:  2018-12-28       Impact factor: 2.021

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.